Adare Pharmaceuticals, Inc., a clinical-stage pharmaceutical company and global provider of advanced pharmaceutical technologies, has acquired the pharmaceutical technology company, Orbis Biosciences, Inc. of Lenexa, KS. The acquisition will expand Adare’s Technologies business, which develops and manufactures products for global pharmaceutical, animal health and over-the-counter (OTC) markets.

Orbis provides enhanced technologies in a scaled, single-step manufacturing process. Its Precision Particle Fabrication technology is capable of producing uniform particles in size ranges suitable for use in injectable, otic and oral dosage forms. The platform technology can accommodate a broad range of active ingredients, including small molecules, peptides, and proteins. Orbis’s technology includes three platforms: Optimμm for oral delivery; Stratμm for injectable delivery; and Unisun for otic delivery.

Adare’s technologies include: Microcaps for taste-masking via a solvent or aqueous based coacervation process; Diffucaps that incorporates release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals; and the MMTSTM Multi Mini Tablet System in which functional membranes are applied to 1.0-2.0 mm cylindrical tablets to control release rates.

Orbis Biosciences will maintain its operations in Lenexa, KS and integration of the companies is underway.